DIA1N Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
DIA1N FAQ
What was DiaSorin S.p.A.’s price range in the past 12 months?
Currently, no data Available
What is DiaSorin S.p.A.’s market cap?
DiaSorin S.p.A.’s market cap is $72.06B.
When is DiaSorin S.p.A.’s upcoming earnings report date?
DiaSorin S.p.A.’s upcoming earnings report date is Jul 31, 2026 which is in 6 days.
How were DiaSorin S.p.A.’s earnings last quarter?
DiaSorin S.p.A. released its earnings results on May 07, 2026. The company reported $18.144 earnings per share for the quarter, beating the consensus estimate of $16.848 by $1.296.
Is DiaSorin S.p.A. overvalued?
According to Wall Street analysts DiaSorin S.p.A.’s price is currently Undervalued.
Does DiaSorin S.p.A. pay dividends?
DiaSorin S.p.A. does not currently pay dividends.
What is DiaSorin S.p.A.’s EPS estimate?
DiaSorin S.p.A.’s EPS estimate is 19.56.
How many shares outstanding does DiaSorin S.p.A. have?
Currently, no data Available
What happened to DiaSorin S.p.A.’s price movement after its last earnings report?
DiaSorin S.p.A. reported an EPS of $18.144 in its last earnings report, beating expectations of $16.848. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of DiaSorin S.p.A.?
Currently, no hedge funds are holding shares in MX:DIA1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DiaSorin S.p.A.
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.